Kaplan-Meier analysis of patient survival rates in the Chinese Glioma Genome Atlas (CGGA) database showed no significant difference in survival between primary and recurrent GBM patients with high vs. low HADHA mRNA levels (Fig. 1D, E). Here, HADHA is linked to central nervous system cancer.